Last update 23 Jan 2025

Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K

Basic Info

Related Targets
Nav1.2SIRT1hERG[+2]

Related

1
Drugs associated with Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K
20(S)-Ginsenoside-Rg3
Target
Nav1.2 x PI4K x SIRT1 x hERG x nAChRα9&α10
Mechanism
Nav1.2 blockers [+4]
Active Org.
Chungnam National University College of Medicine [+3]
Originator Org.
Beijing Xinliheng Medical Technology Development Co., Ltd.
Active Indication
Reperfusion Injury [+1]
Inactive Indication
Hepatocellular Carcinoma
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K
NCT04523467
/ Unknown statusNot ApplicableIIT
A Multicentre Randomized Controlled Study of Anti-angiogenic Targeted Drugs Combined With Ginsenoside Rg3 to Improve the Efficacy of Transcatheter Arterial Chemoembolization (TACE) in the Treatment of Unresectable Hepatocellular Carcinoma
100 Clinical Results associated with Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K
Login to view more data
100 Translational Medicine associated with Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K
Login to view more data
0 Patents (Medical) associated with Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free